A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis

A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis

Objectives: Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom onset to remdesivir treatment [SORT] interval) on...

Full description

Bibliographic Details
Main Authors: Ravindra M. Mehta, Sameer Bansal, Suhitha Bysani, Hariprasad Kalpakam
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Earlier initiation
Mortality
Remdesivir
Safety
Severe
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001788

Similar Items

Similar Items